ISPOR's Value Assessment Stakeholder Conference showed its Special Task Force still reaching for clarification around the subject, writes Ansis Helmanis.
Ansis Helmanis
Advertisement
Ansis Helmanis is a former FDA official and founder of RegLink Associates.
Articles by Ansis Helmanis
Harvey Bale, Jr., MD, former Director-General, IFPMA
Jane Henney, MD, Former FDA Commissioner
Advertisement
Latest Updated Articles
IP: Securing a Global Consensus—Can Industry Do It Again?October 1st 2011
Jane Henney: Lessons from the FDA Front LineOctober 1st 2011
- ISPOR Task Force Grapples with Value Questions
September 28th 2016
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12
2
Pharmaceutical Executive Daily: Senate Democrats Seeking Information on MFN Pharma Deals
3
Agentic AI and the Future of Commercial Excellence in Life Sciences
4
Navigating Complexity in Emerging Biotech: Innovations, Integrations, and Initial Hurdles
5